• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David T. MacLaughlin, PhD


  • Namkung J, Song JY, Jo HH, Kim MR, Lew YO, Donahoe PK, MacLaughlin DT, Kim JH.Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.J Clin Endocrinol Metab. 2012 Sep;97(9):3224-30.
  • Chang HL, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin DT, Donahoe PK.Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.Gynecol Oncol. 2011 Jan;120(1):128-34.
  • Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, Maclaughlin DT, Donahoe PK.Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18874-9.
  • MacLaughlin DT, Donahoe PK.Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.Future Oncol. 2010 Mar;6(3):391-405. Review.
  • Papakostas TD, Pieretti-Vanmarcke R, Nicolaou F, Thanos A, Trichonas G, Koufomichali X, Anago K, Donahoe PK, Teixeira J, MacLaughlin DT, Vavvas D.Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.Protein Expr Purif. 2010 Mar;70(1):32-8.
  • Chang HL,Pahlavan N,Halpern EF,Maclaughlin DT.Serum Mullerian Inhibiting Substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.Gynecol Oncol. 2009 Jul;114(1):57-60.
  • Song JY,Chen KY,Kim SY,Kim MR,Ryu KS,Cha JH,Kang CS,Maclaughlin DT,Kim JH.The expression of Mullerian inhibiting substance/anti-Mullerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.Int J Oncol. 2009 Jun;34(6):1583-91.
  • Nam SW,Jo YS,Eun JW,Song JY,Ryu KS,Lee JY,Lee JM,Maclaughlin DT,Kim JH.Identification of large-scale characteristic genes of Mullerian inhibiting substance in human ovarian cancer cells.Int J Mol Med. 2009 May;23(5):589-96.
  • Fujino A,Arango NA,Zhan Y,Manganaro TF,Li X,MacLaughlin DT,Donahoe PK.Cell migration and activated PI3K/AKT-directed elongation in the developing rat Mullerian duct.Dev Biol. 2009 Jan 15;325(2):351-62.
  • Gupta V, Yeo G, Kawakubo H, Rangnekar V, Ramaswamy P, Hayashida T, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.Cancer Res. 2007 Mar 15;67(6):2747-56.
  • Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31.
  • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
  • Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.Development. 2006 Jun;133(12):2359-69.
  • Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.Clin Cancer Res. 2006 Mar 1;12(5):1593-8.
  • Gupta V, Carey J, Kawakubo H, Muzikansky A, Green J, Donahoe PK, MacLaughlin DT, Maheswaran S.Mullerian Inhibiting Substance suppresses tumor grown in the C3(1)T antigen transgenic mouse mammary carcinoma model.Proc Natl Acad Sci U S A. 2005 MAR 01;102(9):3219-3224.
  • Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB.Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.Fertil Steril. 2005 Jan;83(1):130-6.
  • Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK.Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6.
  • Hoshiya M, Christian BP, Cromie WJ, Kim H, Zhan Y, MacLaughlin DT, Donahoe PK.Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene.Birth Defects Res A Clin Mol Teratol. 2003 Oct;67(10):868-74.
  • Lee MM, Misra M, Donahoe PK, MacLaughlin DT.MIS/AMH in the assessment of cryptorchidism and intersex conditions.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):91-8.
  • Misra M, MacLaughlin DT, Donahoe PK, Lee MM.The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization.J Clin Endocrinol Metab. 2003 Feb;88(2):787-92.
  • Madsusmita M, MacLaughlin DT, Donahoe PK, Lee MM.The Role of Müllerian Inhibiting Substance in the Evaluation of Phenotypic Female Patients with Mild Degrees of Virilization .Journal of Endocrinology and Metabolism. 2003 Feb;88(2).
  • Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT.Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.Clin Cancer Res. 2002 Aug;8(8):2640-6.
  • Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT.New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98.
  • Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44.
  • Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo.J Biol Chem. 2001 Jul 20;276(29):26799-806.
  • Stephen AE, Masiakos PT, Segev DL, Vacanti JP, Donahoe PK, MacLaughlin DT.Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9.
  • Trbovich AM, Sluss PM, Laurich VM, O'Neill FH, MacLaughlin DT, Donahoe PK, Teixeira J.Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3393-7.
  • Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.J Biol Chem. 2000 Sep 15;275(37):28371-9.
  • Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.Clin Cancer Res. 1999 Nov;5(11):3488-99.
  • Lee MM, Seah CC, Masiakos PT, Sottas CM, Preffer FI, Donahoe PK, Maclaughlin DT, Hardy MP.Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells.Endocrinology. 1999 Jun;140(6):2819-27.
  • Lane AH, Lee MM, Fuller AF, Kehas DJ, Donahoe PK, MacLaughlin DT.Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.Gynecol Oncol. 1999 Apr;73(1):51-5.
  • Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, Chang YC, MacLaughlin DT.Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads.N Engl J Med. 1997 May 22;336(21):1480-6.
  • Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT.Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.J Clin Endocrinol Metab. 1996 Feb;81(2):571-6.
  • Maggard MA, Catlin EA, Hudson PL, Donahoe PK, MacLaughlin DT.Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.Metabolism. 1996 Feb;45(2):190-5.
  • Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK.Developmental expression of a candidate müllerian inhibiting substance type II receptor.Endocrinology. 1996 Jan;137(1):160-5.
  • Meyers-Wallen VN, MacLaughlin D, Palmer V, Donahoe PK.Mullerian-inhibiting substance secretion is delayed in XX sex-reversed dog embryos.Mol Reprod Dev. 1994 Sep;39(1):1-7.
  • Hirobe S, He WW, Gustafson ML, MacLaughlin DT, Donahoe PK.Müllerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or graafian follicle selection.Biol Reprod. 1994 Jun;50(6):1238-43.
  • Lee MM, Gustafson ML, Ukiyama E, Donahoe PK, MacLaughlin DT, Wexler M, Keeping HS.Developmental changes in mullerian inhibiting substance in the cynomolgus monkey, Macaca fascicularis.J Clin Endocrinol Metab. 1994 Mar;78(3):615-21.
  • Catlin EA, Ezzell RM, Donahoe PK, Gustafson ML, Son EV, MacLaughlin DT.Identification of a receptor for human müllerian inhibiting substance.Endocrinology. 1993 Dec;133(6):3007-13.
  • Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT, Donahoe PK.Müllerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities.J Pediatr Surg. 1993 Mar;28(3):439-44.
  • Ragin RC, Donahoe PK, Kenneally MK, Ahmad MF, MacLaughlin DT.Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects.Protein Expr Purif. 1992 Jun;3(3):236-45.
  • Catlin EA, Ezzell RM, Donahoe PK, Manganaro TF, Ebb RG, MacLaughlin DT.Mullerian inhibiting substance binding and uptake.Dev Dyn. 1992 Apr;193(4):295-9.
  • Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, Muntz HG, Donahoe PK, MacLaughlin DT, Fuller AF.Müllerian inhibiting substance as a marker for ovarian sex-cord tumor.N Engl J Med. 1992 Feb 13;326(7):466-71.